Rheumatologists now have another treatment option to offer their patients with one of, if not the most, difficult autoimmune diseases to treat. New data add to the growing evidence of the safety and benefit of stem cell transplantation for patients with systemic sclerosis with internal organ involvement.
Explore this issueJune 2017
Also by this Author
New results of the Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial show that patients with systemic sclerosis with lung involvement who underwent myeloablative autologous hematopoietic stem cell transplantation (HSCT) had superior long-term outcomes compared with patients treated with monthly intravenous cyclophosphamide (CYC).
Reporting on the results of the trial at the 2016 ACR/ARHP Annual Meeting, Keith Sullivan, MD, James B. Wyngaarden Professor of Medicine in the Division of Cellular Therapy, Duke University Medical Center, Durham, N.C., says the results suggest it’s time to consider this treatment approach for select patients with systemic sclerosis with early, severe internal organ involvement.1